RXRX Stock Price Today (September 2026) — Recursion Pharmaceuticals, Inc. Analysis & Key Metrics 2026-09-03
Recursion Pharmaceuticals, Inc. (RXRX) is trading at $3.44, up 1.78% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $7.22 (109.8% upside).
- Volatility remains elevated (69.47% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-60.10% YoY) alongside significant competitive pressures.
RXRX Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Recursion Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $1.31B
P/E Ratio
Forward P/E: -3.80
Revenue Growth
Year over Year
Analyst Target
+109.8% upside potential
Key Investor Questions About RXRX
What investors need to know before buying
Based on current market data, RXRX presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 55.05)
- Fundamentals say: Challenging (declining revenue trends)
RXRX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for RXRX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $66.64M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, RXRX stock traded between $2.77 and $7.18—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 69.47% annualized volatility and β=2.51, the stock exhibits high sensitivity to market moves—making RXRX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Tayl
These Are the Stocks Wall Street Is Betting Against the Most
Wolfspeed, BigBear.ai and Others Face Heavy Short-Seller Pressure
Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Recursion Pharmaceuticals, Inc.'s Q2 2026 earnings call
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028. The
Explore More Analysis for RXRX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at $3.44. The RSI (14-day) is at 55.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $7.22 implies 109.8% upside from current levels. Volatility is high at 69.5% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Recursion Pharmaceuticals, Inc. (RXRX): The trailing P/E ratio is -3.44, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -3.80, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 2.01. Price-to-Sales is 33.57. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 6 analysts covering RXRX, the consensus price target is $7.22. This represents a 109.8% upside from the current price of $3.44. The range spans from a low target of $4.00 to a high target of $10.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Recursion Pharmaceuticals, Inc. (RXRX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Recursion Pharmaceuticals, Inc. (RXRX) investors include: 1. High volatility (69.5% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-60.1% YoY), indicating potential business headwinds. 3. Elevated short interest (34.8% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Recursion Pharmaceuticals, Inc.'s (RXRX) current debt and financial health profile: Total debt stands at $66.64M. The debt-to-equity ratio is 7.28, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 5.03, indicating strong short-term liquidity. The quick ratio is 4.67. The company holds $545.68M in cash and equivalents. Free cash flow is negative at $-219,493,744, which could limit the company's ability to manage debt obligations.